6-month, Open-label, Randomized, Multicenter, Prospective, Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program.
Phase of Trial: Phase IV
Latest Information Update: 26 Jun 2014
At a glance
- Drugs Basiliximab (Primary) ; Everolimus (Primary) ; Ciclosporin; Mycophenolate sodium
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms SENATOR
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-005109-20).